Literature DB >> 19795476

Levosulpiride-induced movement disorders.

Hae-Won Shin1, Mi J Kim, Jong S Kim, Myoung C Lee, Sun J Chung.   

Abstract

Levosulpiride is a substituted benzamide that is widely used for the management of dyspepsia and emesis. However, little is known about levosulpiride-induced movement disorders (LIM). The aim of this study was to investigate the clinical characteristics of patients with LIM. Among 132 consecutive patients who were diagnosed with drug-induced movement disorders between January 2002 and March 2008, 91 patients with LIM were identified and their medical records reviewed. Seventy-eight (85.7%) patients were aged more than 60 years. The most common LIM was parkinsonism (LIP) (n = 85, 93.4%), followed by tardive dyskinesia (n = 9, 9.9%) and isolated tremor (n = 3, 3.3%). Twenty-one (24.7%) of the 85 patients with LIP were rated as Hoehn and Yahr stage III-V. The oro-lingual area was the only body part that was involved by tardive dyskinesia. LIM persisted after withdrawal of levosulpiride in 48.1% of patients with LIP, 66.7% with dyskinesia, and none with isolated tremor. None of clinical and MRI features predicted the reversibility of LIP. Levosulpiride frequently causes drug-induced movement disorders, presenting mainly with LIP followed by lower face dyskinesia. The symptoms are often severe, and irreversible even after the withdrawal of levosulpiride. Physicians should be cautious in using levosulpiride, especially in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19795476     DOI: 10.1002/mds.22805

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  23 in total

1.  Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case-Control Study in South Korea.

Authors:  Hae-Young Park; Ji-Won Park; Hyun Soon Sohn; Jin-Won Kwon
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

2.  Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography.

Authors:  Hae-Won Shin; Jae Seung Kim; Minyoung Oh; Sooyeoun You; Young Jin Kim; Juyeon Kim; Mi-Jung Kim; Sun Ju Chung
Journal:  Neurol Sci       Date:  2014-09-18       Impact factor: 3.307

Review 3.  Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Mov Disord       Date:  2018-03       Impact factor: 10.338

Review 4.  Prokinetics in the Management of Functional Gastrointestinal Disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2017-09-08

5.  Drug-induced parkinsonism.

Authors:  Hae-Won Shin; Sun Ju Chung
Journal:  J Clin Neurol       Date:  2012-03-31       Impact factor: 3.077

6.  Levosulpiride-induced Movement Disorders: A Compelling Case for Prudent Use!

Authors:  Divya M Radhakrishnan; Vinay Goyal
Journal:  Ann Indian Acad Neurol       Date:  2020-07-08       Impact factor: 1.383

7.  Cognitive Dysfunction in Drug-induced Parkinsonism Caused by Prokinetics and Antiemetics.

Authors:  Hyun Jung Ahn; Woo-Kyoung Yoo; Jaeseol Park; Hyeo-Il Ma; Yun Joong Kim
Journal:  J Korean Med Sci       Date:  2015-08-13       Impact factor: 2.153

8.  Dropped Head Syndrome after Minor Trauma in a Patient with Levosulpiride-Aggravated Vascular Parkinsonism.

Authors:  Soo Hyun Cho; Dokyung Lee; Tae-Beom Ahn
Journal:  J Mov Disord       Date:  2016-03-28

9.  Pharmacokinetics of levosulpiride after single and multiple intramuscular administrations in healthy Chinese volunteers.

Authors:  Chuting Gong; Janvier Engelbert Agbokponto; Wen Yang; Ernest Simpemba; Xiaohong Zheng; Quanying Zhang; Li Ding
Journal:  Acta Pharm Sin B       Date:  2014-07-03       Impact factor: 11.413

10.  Association of pre-operative medication use with post-operative delirium in surgical oncology patients receiving comprehensive geriatric assessment.

Authors:  Young Mi Jeong; Eunsook Lee; Kwang-Il Kim; Jee Eun Chung; Hae In Park; Byung Koo Lee; Hye Sun Gwak
Journal:  BMC Geriatr       Date:  2016-07-07       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.